{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:51:45Z","timestamp":1792047105779,"version":"4.4.0"},"reference-count":60,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2015,12,22]]},"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of a concentrated formulation of insulin glargine (Gla-300) with other basal insulin therapies in patients with type 2 diabetes mellitus (T2DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This was a network meta-analysis (NMA) of randomised clinical trials of basal insulin therapy in T2DM identified via a systematic literature review of Cochrane library databases, MEDLINE and MEDLINE In-Process, EMBASE and PsycINFO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>Changes in HbA1c (%) and body weight, and rates of nocturnal and documented symptomatic hypoglycaemia were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>41 studies were included; 25 studies comprised the main analysis population: patients on basal insulin-supported oral therapy (BOT). Change in glycated haemoglobin (HbA1c) was comparable between Gla-300 and detemir (difference: \u22120.08; 95% credible interval (CrI): \u22120.40 to 0.24), neutral protamine Hagedorn (NPH; 0.01; \u22120.28 to 0.32), degludec (\u22120.12; \u22120.42 to 0.20) and premixed insulin (0.26; \u22120.04 to 0.58). Change in body weight was comparable between Gla-300 and detemir (0.69; \u22120.31 to 1.71), NPH (\u22120.76; \u22121.75 to 0.21) and degludec (\u22120.63; \u22121.63 to 0.35), but significantly lower compared with premixed insulin (\u22121.83; \u22122.85 to \u22120.75). Gla-300 was associated with a significantly lower nocturnal hypoglycaemia rate versus NPH (risk ratio: 0.18; 95% CrI: 0.05 to 0.55) and premixed insulin (0.36; 0.14 to 0.94); no significant differences were noted in Gla-300 versus detemir (0.52; 0.19 to 1.36) and degludec (0.66; 0.28 to 1.50). Differences in documented symptomatic hypoglycaemia rates of Gla-300 versus detemir (0.63; 0.19to 2.00), NPH (0.66; 0.27 to 1.49) and degludec (0.55; 0.23 to 1.34) were not significant. Extensive sensitivity analyses supported the robustness of these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NMA comparisons are useful in the absence of direct randomised controlled data. This NMA suggests that Gla-300 is also associated with a significantly lower risk of nocturnal hypoglycaemia compared with NPH and premixed insulin, with glycaemic control comparable to available basal insulin comparators.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2015-009421","type":"journal-article","created":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T21:53:22Z","timestamp":1455573202000},"page":"e009421","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":53,"title":["Safety and efficacy of insulin glargine 300\u2005u\/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis"],"prefix":"10.1136","volume":"6","author":[{"given":"Nick","family":"Freemantle","sequence":"first","affiliation":[{"name":"Department of Primary Care and Population Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engels","family":"Chou","sequence":"additional","affiliation":[{"name":"Global Evidence & Value Development\/Health Economics & Outcomes Research, Sanofi, Bridgewater, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Frois","sequence":"additional","affiliation":[{"name":"Analysis Group, AG, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Zhuo","sequence":"additional","affiliation":[{"name":"Analysis Group, AG, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Lehmacher","sequence":"additional","affiliation":[{"name":"Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Vlajnic","sequence":"additional","affiliation":[{"name":"Global Medical Affairs Diabetes, Sanofi, Bridgewater, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Wang","sequence":"additional","affiliation":[{"name":"Global Evidence & Value Development\/Health Economics & Outcomes Research, Sanofi, Bridgewater, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsing-wen","family":"Chung","sequence":"additional","affiliation":[{"name":"TechData Service Company, LLC, King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanwu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Global Evidence & Value Development\/Health Economics & Outcomes Research, Sanofi, Bridgewater, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wu","sequence":"additional","affiliation":[{"name":"Analysis Group, AG, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Gerrits","sequence":"additional","affiliation":[{"name":"Global Evidence & Value Development\/Health Economics & Outcomes Research, Sanofi, Bridgewater, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,2,15]]},"reference":[{"key":"2025121219501100000_6.2.e009421.1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas: sixth edition. http:\/\/www.idf.org\/diabetesatlas (accessed 21 Mar 2014)."},{"key":"2025121219501100000_6.2.e009421.2","unstructured":"World Health Organization. Diabetes Fact Sheet. http:\/\/www.who.int\/mediacentre\/factsheets\/fs312\/en\/ (accessed 1 May 2015)."},{"key":"2025121219501100000_6.2.e009421.3","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441"},{"key":"2025121219501100000_6.2.e009421.4","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12415"},{"key":"2025121219501100000_6.2.e009421.5","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12283"},{"key":"2025121219501100000_6.2.e009421.6","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0991"},{"key":"2025121219501100000_6.2.e009421.7","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0990"},{"key":"2025121219501100000_6.2.e009421.8","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12438"},{"key":"2025121219501100000_6.2.e009421.9","unstructured":"National Institute for Health and Care Excellence. Evidence SynthesisTechnical Support Documents. http:\/\/www.nicedsu.org.uk\/evidence-synthesis-tsd-series%282391675%29.htm (accessed 1 May 2015)."},{"key":"2025121219501100000_6.2.e009421.10","unstructured":"Aschner P , Sethi B , Gomez-Peralta F , et al . Glargine vs. premixed insulin for management of type 2 diabetes patients failing oral antidiabetic drugs: the GALAPAGOS study. Barcelona: EASD, 2013:49"},{"key":"2025121219501100000_6.2.e009421.11","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-2117"},{"key":"2025121219501100000_6.2.e009421.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01165.x"},{"key":"2025121219501100000_6.2.e009421.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01287.x"},{"key":"2025121219501100000_6.2.e009421.14","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-949655"},{"key":"2025121219501100000_6.2.e009421.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2005.09.004"},{"key":"2025121219501100000_6.2.e009421.16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4158\/EP10079.OR","article-title":"A comparison of twice-daily biphasic insulin aspart 70\/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study","volume":"17","author":"Ligthelm","year":"2011","journal-title":"Endocr Pract"},{"key":"2025121219501100000_6.2.e009421.17","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.2.260"},{"issue":"(Suppl 1)","key":"2025121219501100000_6.2.e009421.18","first-page":"A113","article-title":"Comparison of 3 intensified insulin regimens added to oral therapy for type 2 diabetes: twice-daily aspart premixed vs glargine plus 1 prandial glulisine or stepwise addition of glulisine to glargine","volume":"60","author":"Riddle","year":"2011","journal-title":"Diabetes"},{"key":"2025121219501100000_6.2.e009421.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.11.016"},{"key":"2025121219501100000_6.2.e009421.20","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-1122"},{"key":"2025121219501100000_6.2.e009421.21","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903354674"},{"key":"2025121219501100000_6.2.e009421.22","unstructured":"Tinahones FJ , Gross JL , Onaca A , et al . Insulin lispro mix 25\/75 twice daily (LM25) vs basal insulin glargine once daily and prandial insulin lispro once daily (BP) in type 2 diabetes: insulin intensification. Barcelona: EASD, 2013:49."},{"key":"2025121219501100000_6.2.e009421.23","unstructured":"Vora J , Cohen N , Evans M , et al . Glycemic control and treatment satisfaction in type 2 diabetes: basal plus compared with biphasic insulin in the LANSCAPE trial. Barcelona: EASD, 2013:49."},{"key":"2025121219501100000_6.2.e009421.24","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-12-200306170-00006"},{"key":"2025121219501100000_6.2.e009421.25","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-39080"},{"key":"2025121219501100000_6.2.e009421.26","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.11.3080"},{"key":"2025121219501100000_6.2.e009421.27","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.4.631"},{"key":"2025121219501100000_6.2.e009421.28","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00125-009-1415-7","article-title":"Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study","volume":"52","author":"Rosenstock","year":"2009","journal-title":"Diabetologia"},{"key":"2025121219501100000_6.2.e009421.29","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-0132-0"},{"key":"2025121219501100000_6.2.e009421.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60205-0"},{"key":"2025121219501100000_6.2.e009421.31","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2329"},{"key":"2025121219501100000_6.2.e009421.32","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1668"},{"key":"2025121219501100000_6.2.e009421.33","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1205"},{"key":"2025121219501100000_6.2.e009421.34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-8587(13)70013-5","article-title":"Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials","volume":"1","author":"Zinman","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025121219501100000_6.2.e009421.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.11.001"},{"key":"2025121219501100000_6.2.e009421.36","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12083"},{"key":"2025121219501100000_6.2.e009421.37","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.989"},{"key":"2025121219501100000_6.2.e009421.38","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-007-0911-x"},{"key":"2025121219501100000_6.2.e009421.39","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2294"},{"key":"2025121219501100000_6.2.e009421.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa075392"},{"key":"2025121219501100000_6.2.e009421.41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00915.x"},{"key":"2025121219501100000_6.2.e009421.42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2004.00373.x"},{"key":"2025121219501100000_6.2.e009421.43","doi-asserted-by":"publisher","DOI":"10.2337\/dc05-1365"},{"key":"2025121219501100000_6.2.e009421.44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02483.x"},{"key":"2025121219501100000_6.2.e009421.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.10.020"},{"key":"2025121219501100000_6.2.e009421.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2004.03.003"},{"key":"2025121219501100000_6.2.e009421.47","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.2.254"},{"key":"2025121219501100000_6.2.e009421.48","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.diabres.2010.04.002","article-title":"Effects of insulin initiation on patient-reported outcomes in patients with type 2 diabetes: results from the durable trial","volume":"89","author":"Lee","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"2025121219501100000_6.2.e009421.49","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejim.2006.09.006","article-title":"Basal insulin or premix analogue therapy in type 2 diabetes patients","volume":"18","author":"Raskin","year":"2007","journal-title":"Eur J Intern Med"},{"key":"2025121219501100000_6.2.e009421.50","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.8.1130"},{"key":"2025121219501100000_6.2.e009421.51","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0006"},{"key":"2025121219501100000_6.2.e009421.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2008.04.007"},{"key":"2025121219501100000_6.2.e009421.53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01232.x"},{"key":"2025121219501100000_6.2.e009421.54","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12485"},{"key":"2025121219501100000_6.2.e009421.55","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12147"},{"key":"2025121219501100000_6.2.e009421.56","doi-asserted-by":"publisher","DOI":"10.1177\/0145721714529608"},{"key":"2025121219501100000_6.2.e009421.57","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/dom.12070","article-title":"A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function","volume":"15","author":"Brod","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2025121219501100000_6.2.e009421.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.09.002"},{"key":"2025121219501100000_6.2.e009421.59","doi-asserted-by":"publisher","DOI":"10.4158\/EP13287.OR"},{"key":"2025121219501100000_6.2.e009421.60","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-014-0698-4"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2015-009421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T03:50:19Z","timestamp":1765597819000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2015-009421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":60,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,15]]},"published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1136\/bmjopen-2015-009421"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2015-009421","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}